🏛️ Verified NIH Record • Updated 2026-06-10

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (NCT02584933)

An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Who can join: Review the eligibility criteria below.

Location: Highlands Oncology Group — Fayetteville, Arkansas

Age range: 12 Years to 100 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (71 Sites)

Showing the first 25 of 71 sites.

  • Highlands Oncology Group — Fayetteville, Arkansas
  • Loma Linda University — Loma Linda, California
  • University of Colorado Cancer Center — Aurora, Colorado
  • Maryland Oncology Hematology P A — Rockville, Maryland
  • Essex Oncology of North Jersey PA — Belleville, New Jersey
  • Novartis Investigative Site — Melbourne, Victoria
  • Novartis Investigative Site — Auckland,
  • Novartis Investigative Site — Leuven,
  • Novartis Investigative Site — Natal, Rio Grande do Norte
  • Novartis Investigative Site — Porto Alegre, Rio Grande do Sul
  • Novartis Investigative Site — Barretos, São Paulo
  • Novartis Investigative Site — São Paulo, São Paulo
  • Novartis Investigative Site — Sofia,
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Changchun, Jilin
  • Novartis Investigative Site — Beijing,
  • Novartis Investigative Site — Guangzhou,
  • Novartis Investigative Site — Montería,
  • Novartis Investigative Site — Brno,
  • Novartis Investigative Site — Paris,
  • Novartis Investigative Site — Paris,
  • Novartis Investigative Site — Saint-Herblain,
  • Novartis Investigative Site — Strasbourg,
  • Novartis Investigative Site — Villejuif,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All ALK Positive Malignancies clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗